Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations

Slide collection

231,781-231,810 of 319,975

filter-aware
01
Slide 1
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
02
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
03
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
04
The slide uses a grid layout to present six distinct value propositions for the company.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
05
The slide uses a standard pharmaceutical pipeline visualization format.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Roadmap1 hit
06
The slide uses a four-column layout to structure the disease landscape.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
07
Uses a Venn/concentric circle diagram to show the funnel from total infected to diagnosed to treated.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Problem StatementLoop · Aha Moment1 hit
08
The slide uses a process-oriented flow diagram to explain the therapeutic strategy.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Aha Moment1 hit
09
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
10
The slide highlights the mechanism of action and key benefits of the drug candidate.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
11
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Key Takeaways1 hit
12
The slide outlines a clinical trial protocol with specific patient counts (n=43, 12, 13, 8, 10) and timeline milestones (weeks 1, 24, 28, 40, 52).Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
13
Data presented at EASL 2024. Includes specific patient counts and percentages for Cohorts A1 and A2.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Traction1 hit
14
Data presented at EASL 2024. LLOQ = 0.05 IU/mL.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Traction1 hit
15
The slide outlines two parallel study arms involving Imdusiran, VTP-300, NA, and Nivolumab.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Traction1 hit
16
Data presented at EASL 2024. Includes stacked bar charts for threshold achievement and line chart for mean levels over 72 weeks.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Traction1 hit
17
Data presented at EASL 2024. Includes pie charts comparing Group A and Group B across three metrics: time off NA therapy, HBV DNA levels, and HBsAg levels.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Traction1 hit
18
The slide outlines a clinical trial structure with three cohorts (A, B, C) and a follow-up period, totaling 48 weeks.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
19
The slide details a specific licensing deal with financial terms and geographic scope.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
20
Uses a 'deal' framing to appeal to shareholder fairness and fiduciary consistency.Tesla | Shareholder Engagement Presentation Deck | 30 slides · Tesla
Shareholder letter Investor relations 1 hit
21
Uses a before-after framing to address shareholder concerns.Tesla | Shareholder Engagement Presentation Deck | 30 slides · Tesla
Shareholder letter Investor relations 1 hit
22
The slide uses a dark, high-contrast aesthetic typical of Tesla's corporate communications.Tesla | Shareholder Engagement Presentation Deck | 30 slides · Tesla
Shareholder letter Investor relations Beat · Action1 hit
23
Tesla | Shareholder Engagement Presentation Deck | 30 slidesTesla | Shareholder Engagement Presentation Deck | 30 slides · Tesla
Shareholder letter Investor relations Beat · Action1 hit
24
This slide is part of a defense strategy to preemptively rebut concerns about board independence.Tesla | Shareholder Engagement Presentation Deck | 30 slides · Tesla
Shareholder letter Investor relations Beat · Action1 hit
25
Tesla | Shareholder Engagement Presentation Deck | 30 slidesTesla | Shareholder Engagement Presentation Deck | 30 slides · Tesla
Shareholder letter Investor relations Beat · Action1 hit
26
Tesla | Shareholder Engagement Presentation Deck | 30 slidesTesla | Shareholder Engagement Presentation Deck | 30 slides · Tesla
Shareholder letter Investor relations Beat · Action1 hit
27
Tesla | Shareholder Engagement Presentation Deck | 30 slidesTesla | Shareholder Engagement Presentation Deck | 30 slides · Tesla
Shareholder letter Investor relations Beat · Action1 hit
28
Tesla | Shareholder Engagement Presentation Deck | 30 slidesTesla | Shareholder Engagement Presentation Deck | 30 slides · Tesla
Shareholder letter Investor relations Beat · Action1 hit
29
This is a web page screenshot acting as a navigation hub for investor materials.Tesla | Shareholder Engagement Presentation Deck | 30 slides · Tesla
Shareholder letter Investor relations Beat · Action1 hit
30
The slide consists of a tweet by whatsupfranks and a reply by Elon Musk.Tesla | Shareholder Engagement Presentation Deck | 30 slides · Tesla
Shareholder letter Investor relations Beat · Action1 hit